Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Durvalumab |
Indication/Tumor Type | lung non-small cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | lung non-small cell carcinoma | predicted - sensitive | Durvalumab | Phase II | Actionable | In a Phase II trial (ATLANTIC), Imfinzi (durvalumab) treatment resulted in superior objective response rate in non-small cell lung cancer patients with 25% or more tumor cells expressing CD274 (PD-L1) compared to patients with CD274 (PD-L1) expression in less than 25% of tumor cells, in both the cohort harboring EGFR and ALK mutations (12.2% vs 3.6%) and the EGFR and ALK wild-type cohort (16.4% vs 7.5%) (PMID: 29545095; NCT02087423). | 29545095 |
CD274 positive | lung non-small cell carcinoma | predicted - sensitive | Durvalumab | Phase II | Actionable | In a Phase II trial (SAVIMMUNE), Imfinzi (durvalumab) treatment demonstrated safety and resulted in an 8-week objective response rate (ORR) of 26%, and 16-week ORR of 24%, median progression-free survival of 2.3 months, median overall survival (OS) of 6.9 months, a 12-month OS rate of 40%, and a median duration of response of 11.3 months in patients with advanced CD274 (PD-L1)-positive (TPS >/=25%) non-small cell lung cancer with a performance score of 2 or 3 (Ann Oncol (2024) 35 (suppl_2): S842). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
(29545095) | Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. | Full reference... |
1324P Durvalumab in treatment-naive, stage IV non-small cell lung cancer (NSCLC) patients (pts), with ECOG performance status (PS) 2-3 and high PD-L1 tumour expression: Results of IFCT-1802 SAVIMMUNE phase II trial | Full reference... |